Does Aranesp Treat Anemia?
Aranesp (darbepoetin alfa) treats anemia in patients with chronic kidney disease (CKD), including those on dialysis and not on dialysis. It stimulates red blood cell production by mimicking erythropoietin, a hormone kidneys produce to combat anemia from low erythropoietin levels.[1][2]
How Does Aranesp Work for Anemia?
Aranesp binds to erythropoietin receptors on bone marrow cells, promoting their growth into red blood cells. Administered via injection, it raises hemoglobin levels, reducing the need for blood transfusions in CKD-related anemia. Clinical trials showed it increased hemoglobin from about 9 g/dL to 12-13 g/dL over 4-6 weeks in dialysis patients.[2][3]
What Types of Anemia Does It Help?
Primarily CKD-induced anemia. The FDA approves it for:
- Anemia in CKD patients on dialysis.
- Anemia in CKD patients not on dialysis to avoid transfusions.
It is not approved for anemia from cancer chemotherapy, though off-label use occurs in some cases.[1][4]
Common Side Effects and Risks
Patients report hypertension, injection-site pain, and fluid retention. Serious risks include blood clots, stroke, heart attack, and tumor progression in cancer patients. Black-box warnings highlight increased mortality and cardiovascular events at high hemoglobin targets (>11 g/dL). Monitoring hemoglobin closely is required.[1][2]
How Does Aranesp Compare to Epogen or Procrit?
All are erythropoiesis-stimulating agents (ESAs). Aranesp has a longer half-life (about 48 hours vs. 8-12 hours for Epogen/epoetin alfa), allowing less frequent dosing (every 1-2 weeks vs. 3x/week). Similar efficacy in CKD anemia, but Aranesp costs more per dose.[3][5]
Who Makes Aranesp and What's the Pricing?
Amgen manufactures Aranesp. Average U.S. wholesale price is $300-$500 per 100 mcg dose, varying by pharmacy and insurance. Biosimilars are not yet approved in the U.S.[6]
When Do Aranesp Patents Expire?
Key U.S. patents expired in 2024, opening potential biosimilar entry. Check DrugPatentWatch.com for litigation updates and exact expiry dates.[7]
[1]: FDA Label - Aranesp (darbepoetin alfa), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103951s5295lbl.pdf
[2]: Amgen Prescribing Information, https://www.aranesp.com
[3]: New England Journal of Medicine - Darbepoetin Alfa Study (2001), https://www.nejm.org/doi/full/10.1056/NEJMoa011226
[4]: National Kidney Foundation Guidelines, https://www.kidney.org/atoz/content/anemia
[5]: Drug Comparison - Epogen vs. Aranesp, https://www.drugs.com/compare/epogen-vs-aranesp
[6]: GoodRx Pricing Data (2024), https://www.goodrx.com/aranesp
[7]: DrugPatentWatch - Aranesp Patents, https://www.drugpatentwatch.com/p/tradename/ARANESP